A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer-Reference-Cited by-同舟云学术

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Published:2015-08-26 Issue:1 Volume:22 Page:44-53
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Schlumberger Martin,Jarzab Barbara,Cabanillas Maria E.,Robinson Bruce,Pacini Furio,Ball Douglas W.,McCaffrey Judith,Newbold Kate,Allison Roger,Martins Renato G.,Licitra Lisa F.,Shah Manisha H.,Bodenner Donald,Elisei Rossella,Burmeister Lynn,Funahashi Yasuhiro,Ren Min,O'Brien James P.,Sherman Steven I.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer;JCO Oncology Practice;2024-07

2. Expression of vascular endothelial growth factor receptor in thymic epithelial tumors;Oncology Letters;2024-06-18

3. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents;Cell Communication and Signaling;2024-04-15

4. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions;Annales d'Endocrinologie;2024-04

5. Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC);CPT: Pharmacometrics & Systems Pharmacology;2024-03-26